Botanix Pharmaceuticals (ASX:BOT) reported Wednesday a fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.
Revenue for the six months ended Dec. 31, 2024, was AU$345.7 million, compared with AU$377.9 million a year earlier.
The company's shares fell 1% in recent Thursday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。